|Bid||2.1500 x 900|
|Ask||2.5800 x 1100|
|Day's range||2.2000 - 2.3050|
|52-week range||2.1500 - 26.3000|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||28 Mar 2022 - 01 Apr 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||21.00|
Those following along with Angion Biomedica Corp. ( NASDAQ:ANGN ) will no doubt be intrigued by the recent purchase of...
Angion's (ANGN) phase II study evaluating ANG-3777 in cardiac surgery-associated acute kidney injury fails to achieve the primary endpoint.
ST. GALLEN, Switzerland & UNIONDALE, N.Y., December 10, 2021--Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211209006035/en/